Page 64 – Channelchek

Release – Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Posted on April 9, 2025April 9, 2025 by aweinsoff@channelchek.com

April 09, 2025 7:00am EDT Download as PDF

Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation

Establishes framework for Makana’s kidney, heart and islet cell programs to utilize TNX-1500 for preclinical studies in support of regulatory filings for potential use in human recipients

CHATHAM, N.J. and MIAMI, April 09, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), (“Tonix”) a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, and Makana Therapeutics, Inc. (“Makana”), a global leader in the field of xenotransplantation, today announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L (CD40 ligand, also called CD154) monoclonal antibody candidate, TNX-1500, in combination with Makana’s human-compatible organs and cells for the treatment of organ failure. The preclinical research and development collaboration has the potential to span multiple Makana programs including kidney, heart and islet cell transplant. The goal of the preclinical studies is to support the submission of an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) to support compassionate use for patients undergoing xenotransplantation.

“We are excited to partner with Makana in support of our mutual goal to offer novel solutions for patients requiring organ or cellular transplantation,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “We believe this strategic agreement is a promising step towards utilizing xenotransplantation in the clinic. Makana’s novel genetically engineered (GE) pigs, which have deleted swine leukocyte antigen (SLA)², has shown improved human compatibility and several other advantages over other technologies including high rates of fertility and birthing, which potentially increases their ability to produce viable organs to satisfy a commercial market globally.”

“Despite significant progress and momentum in the field of xenotransplantation, improving organ compatibility to prevent rejection remains an ongoing challenge,” said Joseph Tector, M.D., Ph.D., Founder of Makana and a practicing transplant surgeon. “This collaboration provides Makana the opportunity to combine its novel GE pig organs with TNX-1500 in our ongoing and future preclinical studies. We view anti-CD40L as a critical part of an effective immunomodulatory regimen for successful xenotransplantation. This collaboration enables us to pursue co-development of our GE organs with the TNX-1500, which has shown best-in-class pharmacokinetics and pharmacodynamics in a human study after showing best-in-class results in preventing rejection in 6-month studies of allo- and xenotransplantation in animals. Our mutual goal is to obtain the best human results as soon as possible.”

“We are thrilled with this collaboration utilizing TNX-1500 as an important element of our xenotransplant therapy. The collaboration with Tonix gives Makana the right product and the right partner to bring Makana toward clinical development,” said Mark Platt, President and Chief Executive Officer of Makana. “Most organ-failure patients today will never receive a lifesaving/life-changing transplant. Our achievement in developing the SLA DR knockout pig has yielded encouraging results with preclinical kidney xenografts and positions us to deliver strong outcomes in clinical development.”

TNX-1500 is an investigational, humanized Fc-modified IgG4 anti-CD40L antibody with high affinity for the CD40 ligand. CD40L is an attractive drug development target for transplant immunomodulation since the engagement of the CD40L plays a pivotal role in immune system activation by modulating both antibody and cellular immune responses.

About Makana’s Genetically Engineered (GE) Pigs

Makana began developing pigs for xenotransplantation in 2010. Makana’s 2013 creation of the Triple Knockout (TKO) Pig, lacking three key glycans responsible for hyperacute and acute organ rejection in humans, resulted in the first 1-year preclinical xeno-kidney survivor in animals¹. This discovery revitalized the xeno-field and today Makana’s TKO genetics are employed across the xenotransplantation field.

Realizing that the first clinical xenografts failed because of antibody mediated rejection, Makana deferred rushing to the clinic and employed the same stepwise scientific approach to show that these early clinical failures occur because of the development of antibodies against SLA. The final result is that Makana has developed the new TKO plus SLA DR KO pig that eliminates the next barrier to clinical success. Now Makana is poised to achieve longer term clinical success.

Makana has achieved the field’s longest and most consistent preclinical survival without the need to insert human transgenes into its pig genetics. Rejection continues as a barrier to survival in the limited number of emergency IND human transplants performed with transgenic pigs, further supporting Makana’s focus on antigen discovery and deletion in lieu of relying on inserted transgenes to evade the human immune response.

Without the need for transgenes, the future commercialization of Makana’s xeno-organs through breeding will be straightforward. When compared to transgenic animals, Makana’s knockout-only pigs will breed with greater efficiency and eliminate the challenge of retaining transgenic expression. This is an important consideration, reducing both the cost of therapy and the complexity of GE pig production.

Makana’s preclinical successes with SLA-deleted pig kidneys in animal xenotransplantation has depended on the co-administration of primatized 5c8 anti-CD40L monoclonal antibody. Tonix’s TNX-1500 is an Fc-modified version of humanized 5c8, which maintains the activity of 5c8, while improving tolerability.

About TNX-1500

TNX-1500 (Fc-modified humanized anti-CD40L mAb) is a humanized monoclonal antibody that binds and functionally inhibits the CD40-ligand (CD40L), also known as CD154 or 5c8 Ag.⁴ The combining sites of TNX-1500 are derived from humanized 5c8 or ruplizumab, which showed promise in treating systemic lupus erythematosus.⁵ Chimeric primatized 5c8 showed promise in preventing rejection of organ rejection in animals.⁶ TNX-1500 is being developed for the prevention of allograft and xenograft rejection, for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT) and for the treatment of autoimmune diseases. TNX-1500 prevents rejection, prolongs survival and preserves graft function as a single agent or in combination with other drugs in non-human primate renal and heart allografts and renal xenografts.⁷^-9

*TNX-1500 is an investigational new biologic and is not approved for any indication

Citations

Estrada JL, et al. Xenotransplantation. 2015;22(3):194-202.
Reyes LM, et al. J Immunol. 2014;193(11):5751-7.
Lederman S, et al, J Exp Med. 1992;175(4):1091-101. doi: 10.1084/jem.175.4.1091. PMID: 1348081; PMCID: PMC2119166.
Boumpas DT, et. al. Arthritis Rheum. 2003;48(3):719-27. doi: 10.1002/art.10856. PMID: 12632425.
Pierson RN 3rd, et al. Transplantation. 1999;68(11):1800-5. doi: 10.1097/00007890-199912150-00026. PMID: 10609959.
Lassiter G, et al. Am J Transplant. 2023;23(8):1171-1181. doi: 10.1016/j.ajt.2023.03.022.
Miura S, et al. Am J Transplant. 2023;23(8):1182-1193. doi: 10.1016/j.ajt.2023.03.025.
Anand, R.P., et al Nature. 622, 393–401 (2023). https://doi.org/10.1038/s41586-023-06594-4

Tonix Pharmaceuticals Holding Corp.^*

Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace^® SymTouch^® (sumatriptan injection) 3 mg and Tosymra^® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

About Makana Therapeutics

Founded in 2009, Makana Therapeutics is focused on developing swine with reduced xenoantigen expression, making human transplantation of cells, tissues and organs from these animals possible. Makana’s focus on scientifically validated genetics, optimized pig cloning techniques and careful patient selection is expected to streamline product development and result in safer more efficacious products. For more information on Makana, please visit www.makanatherapeutics.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Peter Vozzo
ICR Healthcare
peter.vozzo@icrhealthcare.com
(443) 213-0505

Media Contact

For Tonix:
Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

For Makana:
Mark Leonard
Next Level Agency
mark@reachthenextlevel.com
847-651-9682

Indication and Usage

Zembrace^® SymTouch^® (sumatriptan succinate) injection (Zembrace) and Tosymra^® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded

Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before

The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Source: Tonix Pharmaceuticals Holding Corp.

Released April 9, 2025

Alliance Resource Partners (ARLP) – A Strong U.S. Economy Relies on Abundant, Affordable and Reliable Energy Sources

Posted on April 9, 2025April 9, 2025 by cpereira@noblefcm.com

Wednesday, April 09, 2025

ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil & gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Biden-era policies disadvantaged coal-fired power plants. In May 2024, the Environmental Protection Agency published a final rule that amended the Mercury and Air Toxics Standards (MATS) rule to make it more stringent. The rule placed severe burdens on coal-fired power plants and required compliance with standards premised on the application of costly emissions-control technologies that, for many coal plants, were not commercially viable. The new carbon emission rules were expected to accelerate coal-fired power plant retirements.

Taking a pragmatic and realistic approach. On April 8, President Trump took actions through proclamation and executive order to, 1) reinvigorate the U.S. coal industry, 2) protect American energy from state overreach, 3) strengthen the reliability and security of the United States electric grid, and 4) provide two years of relief from stringent Biden-era environmental regulations by allowing certain coal plants to comply with a less stringent version of the MATS rule. Moreover, the actions are intended to reduce regulatory burdens and promote coal exports.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

V2X, Inc. (VVX) – New Business; Successful ReFi

Posted on April 9, 2025April 9, 2025 by cpereira@noblefcm.com

Wednesday, April 09, 2025

V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

COBRA DANE. V2X has been awarded a $62 million contract extension to continue ensuring the operational readiness of the COBRA DANE radar system in Alaska. In addition to ensuring operational readiness, V2X has incorporated various engineering enhancements into this essential system, extending its capabilities and readiness. This full-spectrum support emphasizes V2X’s differentiated capabilities, in our view. The extension work is expected to be completed by March 2027.

TESS ID/IQ. V2X won a seat on the Bridge to Enduring Synthetic Training Environment Tactical Engagement Simulation Systems (TESS). This contract supports the U.S. Army’s TESS devices, a vital component of its live training capabilities, by extending their product life and ensuring they meet the Army’s evolving requirements. The ID/IQ contract includes a ten-year performance period consisting of a five-year base period and two options with a ceiling value of $921 million. This award complements V2X’s previously won $3.7 billion Warfighter Readiness task order.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Are Small-Caps Oversold? Why Now Might Be the Time to Start Your Shopping List

Posted on April 9, 2025April 9, 2025 by slightbourne@noblecapitalmarkets.com

The current market sentiment is one of extreme fear, with widespread selling across many small-cap stocks, especially those in the Russell 2000 index. A variety of factors, including tariffs and broader market uncertainty, have led to this wholesale selling, and as a result, many fundamentally strong small companies are being punished. However, for those willing to take a closer look, this fear-induced market drop may present some excellent investment opportunities.

On Friday, the Russell 2000 was down 27%, a sharp decline that reflects how smaller companies, particularly those in this index, are feeling the brunt of the market’s volatility. The Russell 2000 is made up of small-cap companies, which are inherently more volatile and have less liquidity than larger companies. As a result, they tend to experience more extreme price swings in response to broader market movements. This has created a situation where many small-cap stocks are now trading at huge discounts.

Take, for example, FreightCar America (RAIL). Just last December, this stock was trading at around $14. Now, it’s hovering around $4.50. Despite the severe decline, this is a stock that is fundamentally sound. The company is exempt from tariffs, has improved its financials with a successful refinancing deal in December, and has a solid business model. Yet, the stock continues to trade lower because of the broader market selloff affecting the Russell 2000 ETF. This creates a disconnect between the company’s true value and its current price.

Similarly, Graham (GHM), a defense manufacturer, was trading at $52 just a few months ago. Today, it’s at $27, representing a 50% discount on a fundamentally strong company. The Trump administration’s push to build more ships should actually work in Graham’s favor, making this steep decline even more perplexing. The fear in the market has led to excessive selling, but for long-term investors, this represents a buying opportunity.

And then there’s Eledon Pharmaceuticals (ELDN), a biopharmaceutical company whose stock has dropped from $5.50 to $2.80. This is a company with improving fundamentals, particularly positive patient data, yet the stock price has fallen sharply. This disconnect between price and performance highlights how the selloff has been more about broader market panic than about the company’s intrinsic value.

The bottom line is that there are real bargains out there in small-cap stocks for individual investors who are willing to look past the short-term fear. The Russell 2000 index has been hit harder than other indexes due to the smaller size and lower liquidity of the companies involved. As a result, the impact of impulsive, panic-driven selling is more pronounced in this index than in the larger ones.

For investors with staying power, particularly those with a 2-3 year horizon, the current market turmoil presents a significant opportunity. Many of these companies, which are being unfairly dragged down by the broader market, have strong fundamentals and the potential to rebound once market sentiment stabilizes. As the market continues to digest these challenges, patient investors may see significant returns as these companies recover and grow.

Release – MariMed Announces First Quarter 2025 Earnings Date

Posted on April 8, 2025April 8, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MRMD

Download as PDF

April 08, 2025 7:30am EDT

NORWOOD, Mass., April 08, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed” or “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today it will report first quarter 2025 financial results on May 7, 2025 after the markets close. Management will host a conference call on May 8, 2025 at 8:00 a.m. EDT to discuss financial results.

A webcast will be available and can be accessed via MariMed’s Investor Relations website at MariMed Q125 Earnings Webcast. A playback of the call will also be made available on MariMed’s Investor Relations website.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, InHouse™, Nature’s Heritage™, and Vibations™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Source: MariMed Inc.

Released April 8, 2025

Release – V2X Delivering Critical Support to U.S. Missile Defense and Space Surveillance Capabilities

Posted on April 8, 2025April 8, 2025 by aweinsoff@channelchek.com

Research News and Market Data on VVX

April 08, 2025

Download(opens in new window)

RESTON, Va., April 8, 2025 /PRNewswire/ — V2X Inc. (NYSE: VVX), has been awarded a $62 million contract to continue its critical work ensuring operational readiness of the COBRA DANE radar system in Alaska. This award solidifies V2X’s position as a leading provider of operational readiness, capability enhancements, and engineering support for COBRA DANE, an extremely powerful and sophisticated radar in the U.S. Space Force arsenal.

“V2X has been the trusted partner in ensuring the continuous operational readiness of COBRA DANE,” said Jeremy C. Wensinger, President and Chief Executive Officer of V2X. “Additionally, V2X has incorporated various engineering enhancement to this essential system, extending its capabilities and readiness. This full-spectrum support emphasizes our differentiated capabilities in radar operations, readiness, and commitment to supporting national security by providing persistent space domain awareness and missile defense.”

Standing 120 feet tall with a 95-foot diameter phased-array face, COBRA DANE is a critical component of the nation’s defense architecture. It can detect and track objects up to 2,000 miles away, supporting U.S. Ballistic Missile Defense. Additionally, the radar plays a key role in space domain awareness, identifying and characterizing satellites and debris in Earth’s orbit.

With this contract extension, V2X continues its legacy in providing full-spectrum mission solutions to ensure the continuous readiness of this essential radar system. The extension work is expected to be completed by March 2027.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Marketing and Communications
Angelica.Deoudes@goV2X.com
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-delivering-critical-support-to-us-missile-defense-and-space-surveillance-capabilities-302422743.html

SOURCE V2X, Inc.

GDEV Inc. (GDEV) – A More Profitable Growth Outlook

Posted on April 8, 2025April 8, 2025 by cpereira@noblefcm.com

Tuesday, April 08, 2025

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q4 results. The company reported Q4 revenue of $97.5 million, modestly lower than our estimate of $101.0 million, but adj. EBITDA of $12.2 million was substantially better than our estimate of a loss of $1.9 million. The adj. EBITDA beat was largely driven by the company’s efficient use of selling and marketing expenses, which were 25% lower than our estimate.

Key operating metrics. In Q4, the company generated $94 million in bookings and had 292,000 monthly paying users (MPU). Bookings were largely in line with our expectations, while MPUs were modestly lower than we anticipated. Importantly, the decrease in MPU’s moderated from the quarter-over-quarter decrease experienced in Q3, and the company’s strategic marketing efforts appear to be gaining traction.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Euroseas (ESEA) – Favorable Time Charter Contract for the M/V Monica

Posted on April 8, 2025April 8, 2025 by cpereira@noblefcm.com

Tuesday, April 08, 2025

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New time charter contract. Euroseas Ltd. executed a time charter contract for the M/V Monica at a gross daily rate of $23,500 for a minimum period of 24 months, with an option to extend to a maximum of 26 months at the charterer’s option. The M/V Monica is a 1,800 twenty-foot equivalent unit (TEU) feeder container ship. The new charter is expected to commence between the end of April and mid-May 2025.

Attractive rate and improved charter coverage. The new time charter is an improvement over the previous contract rate of $16,000 per day and is expected to contribute EBITDA of $12.1 million during the minimum contracted period. The new time charter enhances Euroseas’ charter coverage for the remainder of 2025 and 2026 to ~94% and ~58%, respectively.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Wall Street Roller Coaster: Early Gains Give Way to Sharp Losses Amid 104% Tariff Shock

Posted on April 8, 2025April 8, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– U.S. markets experienced a dramatic reversal on Tuesday afternoon after early gains, following President Trump’s decision to impose a 104% tariff on Chinese imports.
– The benchmark indices reversed their earlier rally: the S&P 500 dipped about 1.6%, the Nasdaq Composite dropped nearly 2.2%, and the Dow slid by roughly 0.8% (around 300 points) after intraday gains exceeding 1,300 points.
– White House officials reiterated that reciprocal tariffs will remain in effect on Wednesday as negotiations continue, even as geopolitical tensions escalate.

In the early session, investors had rallied—the Dow had surged nearly 1,000 points, buoyed by optimism that tariff negotiations, especially with key players such as South Korea and China, might ease trade tensions. Treasury Secretary Scott Bessent had pointed out that around 70 countries were in discussions with Washington, offering a glimmer of hope for relief.

However, that optimism was quickly upended. In a stunning turn of events, President Trump announced the imposition of a 104% tariff on Chinese goods—a move designed to further pressure Beijing in ongoing trade negotiations. The updated trade policy, which was set to go into effect at 12:01 am ET, spurred a sharp reversal in market sentiment. U.S. stocks tumbled in the afternoon session as investors reacted to the unexpected severity of the tariffs.

According to updated market reports, while the Dow had earlier rallied by more than 1,300 points, it eventually closed down roughly 300 points (a loss of about 0.8%). The S&P 500, which had enjoyed gains exceeding 4%, reversed course to fall by approximately 1.6%, narrowly avoiding a full-blown bear market. Likewise, the Nasdaq Composite fell around 2.2%. Data on trading volatility confirmed the dramatic shift; after spiking sharply earlier in the week, sentiment cooled briefly only to plunge following Trump’s tariff announcement.

In a press briefing, White House press secretary Karoline Leavitt reinforced the administration’s hard-line stance, declaring that “Americans do not need other countries as much as other countries need us,” and affirming that President Trump’s resolve would not falter. Meanwhile, Chinese authorities warned that Beijing would “fight to the end” if the U.S. continued with what they termed trade “blackmail,” indicating that any progress in negotiations would be challenging.

Market analysts are now warning that the turnaround in sentiment could presage further volatility unless concrete progress is made on trade negotiations. “There has to be some staying power,” remarked Robert Ruggirello, chief investment officer at Brave Eagle Wealth Management, noting that both corporations and individual investors seek stable, predictable policies before committing to long-term decisions.

As the session ended, while some investors were briefly encouraged by early morning gains and signals of impending deals, the stark reality of the tariff imposition quickly reset expectations. With reciprocal tariffs set to go into effect on Wednesday regardless of ongoing talks, the market faces a period of uncertainty as all eyes remain on the administration and Beijing for any signs of de-escalation.

Wesdome Gold Mines to Acquire Angus Gold in $40 Million Deal, Expanding Eagle River Footprint

Posted on April 8, 2025April 8, 2025 by slightbourne@noblecapitalmarkets.com

Key Points:
– Wesdome expands Eagle River land package from 100 km² to 400 km², unifying exploration potential across multiple zones.
– Offer values Angus shares at a 59% premium with a significant cash component and equity in Wesdome.
– Wesdome plans to advance Angus’ exploration momentum with its resources, infrastructure, and capital strength.

Wesdome Gold Mines Ltd. has announced the acquisition of Angus Gold Inc. in a $40 million deal that significantly expands its land position surrounding the Eagle River mine in Northern Ontario. The transaction, structured as a court-approved plan of arrangement, will see Wesdome acquire all of the issued and outstanding shares of Angus that it does not already own, offering shareholders a combination of cash and Wesdome shares. The offer values Angus at $0.77 per share—comprised of $0.62 in cash and 0.0096 of a Wesdome common share—representing a 59% premium to Angus’ 20-day volume-weighted average price as of April 4, 2025.

The acquisition will consolidate Wesdome’s Eagle River property with Angus’ Golden Sky project, creating a contiguous 400 square kilometre land package in the Mishibishu Lake greenstone belt. Wesdome currently owns about 10.4% of Angus’ shares and 14.9% on a partially diluted basis, and has secured lock-up agreements from shareholders representing approximately 47% of Angus’ outstanding shares. This strategic move positions Wesdome to capitalize on the regional geology and existing infrastructure to unlock value from underexplored zones adjacent to its operating mine.

According to Wesdome CEO Anthea Bath, the acquisition is a “logical and strategic tuck-in” that supports the company’s regional growth strategy and long-term commitment to the Eagle River camp. She emphasized that the acquisition enhances Wesdome’s ability to unlock new discoveries through exploration and complements the company’s goal of optimizing mill capacity with feed from high-potential zones nearby. The move underscores Wesdome’s confidence in the long-term geological potential of the region and its desire to become a more dominant player in the Ontario and Québec gold sectors.

Angus has spent over $20 million on exploration at Golden Sky since 2020, completing more than 40,000 metres of drilling and identifying promising zones like the Eagle River Splay and Cameron Lake banded iron formation. These zones have already delivered high-grade intercepts, and Wesdome intends to focus exploration efforts there in 2025. With its robust balance sheet and existing infrastructure, Wesdome plans to accelerate exploration and development while leveraging stakeholder and Indigenous relationships in the area. The proximity to Wesdome’s existing mill and operational support is expected to reduce timelines and costs associated with bringing any new discoveries into production.

For Angus shareholders, the transaction delivers a compelling financial return and access to a more diversified and capitalized gold producer. In addition to the immediate cash component, shareholders will receive equity in Wesdome, offering continued exposure to the upside potential of the assets they helped advance. Angus CEO Breanne Beh called the deal a validation of her team’s work and a logical next step to realize the full value of the exploration investment made over the past five years.

The deal is subject to shareholder approval, court approval, regulatory clearances, and other customary closing conditions. A special meeting of Angus shareholders is expected to take place in June 2025, with the transaction expected to close in the second quarter. Legal advisors include Stikeman Elliott LLP for Wesdome, and Peterson McVicar LLP and Mason Law LLP for Angus and its Special Committee, respectively. Evans & Evans, Inc. provided a fairness opinion, concluding the offer is fair to Angus shareholders from a financial standpoint.

Release – InPlay Oil Corp. Announces Completion of Strategic Pembina Cardium Oil Asset Acquisition

Posted on April 7, 2025April 7, 2025 by aweinsoff@channelchek.com

Research News and Market Data on IPOOF

Apr 07, 2025, 13:15 ET

CALGARY AB, April 7, 2025 /CNW/ – InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company“) is pleased to announce that it has closed the previously announced strategic acquisition of Cardium light oil focused assets in the Pembina area of Alberta (the “Acquired Assets“) from Obsidian Energy Ltd. (the “Vendor“) for net consideration of approximately $301 million (the “Acquisition“).

The highly accretive Acquisition was funded by a combination of net proceeds released to InPlay pursuant to its previously announced $32.8 million bought deal subscription receipt financing (the “Financing“), an amended $330 million credit facility with a $190 million revolving credit facility, a letter of credit facility of up to $30 million, a fully drawn $110 million two-year amortizing term loan and the issuance of 54,838,709 InPlay common shares to the Vendor at a deemed price of $85 million or $1.55 per share (the “Share Consideration“). The Share Consideration is subject to a six-month lock up period, which may be shortened in certain circumstances.

In accordance with their terms, each one (1) subscription receipt issued pursuant to the Financing was automatically exchanged for one (1) InPlay Share concurrently with the completion of the Acquisition, and the net proceeds were released to InPlay from escrow and used to fund a portion of the cash consideration payable to the Vendor under the Acquisition. Previous holders of subscription receipts of InPlay are not required to take any action to receive the underlying InPlay Shares. Trading in the subscription receipts on the Toronto Stock Exchange is expected to be halted today and the subscription receipts delisted in due course.

Immediately following completion of the Acquisition, InPlay has 167,636,627 InPlay Shares issued and outstanding, inclusive of the underlying 21,145,625 InPlay Shares issued upon conversion of subscription receipts previously issued pursuant to the Financing and the Share Consideration issued to the Vendor.

Concurrent with completion of the Acquisition, InPlay entered into an amended and restated credit agreement with a syndicate of lenders (the “Lenders“) pursuant to which the aggregate available borrowing capacity under InPlay’s Senior Credit Facility has been increased from $110 million to $330 million by way of an increased $190 million revolving credit facility with a term out date extended to June 30, 2026, a fully drawn $110 million two-year amortizing term loan (the “Term Loan“) and a letter of credit facility of up to $30 million. The Term Loan includes quarterly amortization payments of $4.1 million. The covenant and security package under the new Term Loan is substantially the same as the revolving credit facility, with the exception of an additional affirmative covenant to satisfy certain prescribed hedging requirements during the period the Term Loan remains outstanding.

In accordance with a shareholder rights agreement between InPlay and the Vendor, the Vendor nominated Stephen E. Loukas, President and Chief Executive Officer and Peter D. Scott, Senior Vice President and Chief Financial Officer, both of Obsidian Energy Ltd., for election to the InPlay Board of Directors at the Special Meeting. Both nominees were elected as directors of InPlay to serve until the next annual meeting of shareholders or until their successors are elected or appointed. The Vendor nominees have agreed to support the resolutions brought before InPlay shareholders at the 2025 annual general meeting of shareholders.

Reader Advisories

Forward-Looking Information and Statements

This document contains certain forward–looking information and statements within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends”, “forecast” and similar expressions are intended to identify forward-looking information or statements. In particular, but without limiting the foregoing, this document contains forward-looking information and statements pertaining to the following: the Company’s business strategy, milestones and objectives; light crude oil and NGLs weighting estimates; expectations regarding future commodity prices; future oil and natural gas prices; future liquidity and financial capacity; future results from operations and operating metrics; future costs, expenses and royalty rates; future interest costs; the exchange rate between the $US and $Cdn; future development, exploration, acquisition, development and infrastructure activities and related capital expenditures; the amount and timing of capital projects; and methods of funding our capital program.

The internal projections, expectations, or beliefs underlying our Board approved 2025 capital budget and associated guidance are subject to change in light of, among other factors, changes to U.S. economic, regulatory and/or trade policies (including tariffs), the impact of world events including the Russia/Ukraine conflict and war in the Middle East, ongoing results, prevailing economic circumstances, volatile commodity prices, and changes in industry conditions and regulations. InPlay’s 2025 financial outlook and revised guidance provides shareholders with relevant information on management’s expectations for results of operations, excluding any potential acquisitions or dispositions, for such time periods based upon the key assumptions outlined herein. Readers are cautioned that events or circumstances could cause capital plans and associated results to differ materially from those predicted and InPlay’s revised guidance for 2025 may not be appropriate for other purposes. Accordingly, undue reliance should not be placed on same.

Forward-looking statements or information are based on a number of material factors, expectations or assumptions of InPlay which have been used to develop such statements and information, but which may prove to be incorrect. Although InPlay believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because InPlay can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified herein, assumptions have been made regarding, among other things: the current U.S. economic, regulatory and/or trade policies; the impact of increasing competition; the general stability of the economic and political environment in which InPlay operates; the timely receipt of any required regulatory approvals; the ability of InPlay to obtain qualified staff, equipment and services in a timely and cost efficient manner; drilling results; the ability of the operator of the projects in which InPlay has an interest in to operate the field in a safe, efficient and effective manner; the ability of InPlay to obtain debt financing on acceptable terms; the anticipated tax treatment of the monthly base dividend; that other than the tariffs that came into effect on March 4, 2025 (some of which were subsequently paused on March 6, 2025), neither the U.S. nor Canada (i) increases the rate or scope of such tariffs (if they come into effect in the future), or imposes new tariffs, on the import of goods from one country to the other, including on oil and natural gas, and/or (ii) imposes any other form of tax, restriction or prohibition on the import or export of products from one country to the other, including on oil and natural gas; the potential scope and duration of tariffs, export taxes, export restrictions or other trade actions; magnitude and duration of potential new or increased tariffs may be imposed on goods imported from Canada into the United States, which could adversely impact InPlay’s revenues; the potential for new and increased U.S. tariffs and protectionist trade measures on Canadian oil and gas imports; changes in political and economic conditions, including risks associated with tariffs, export taxes, export restrictions or other trade actions; impacts of any tariffs imposed on Canadian exports into the United States by the Trump administration and any retaliatory steps taken by the Canadian federal government; that InPlay’s results and operations could be adversely affected by economic or geopolitical developments, including protectionist trade policies such as tariffs, or other events; conditions in international markets, including social and political conditions, civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, tariffs and other protectionist measures; field production rates and decline rates; the ability to replace and expand oil and natural gas reserves through acquisition, development and exploration; the timing and cost of pipeline, storage and facility construction and the ability of InPlay to secure adequate product transportation; future commodity prices; that various conditions to a shareholder return strategy can be satisfied; the ongoing impact of the Russia/Ukraine conflict and war in the Middle East; currency, exchange and interest rates; regulatory framework regarding royalties, taxes and environmental matters in the jurisdictions in which InPlay operates; and the ability of InPlay to successfully market its oil and natural gas products.

Without limitation of the foregoing, readers are cautioned that the Company’s future dividend payments to shareholders of the Company, if any, and the level thereof will be subject to the discretion of the Board of Directors of InPlay. The Company’s dividend policy and funds available for the payment of dividends, if any, from time to time, is dependent upon, among other things, levels of FAFF, leverage ratios, financial requirements for the Company’s operations and execution of its growth strategy, fluctuations in commodity prices and working capital, the timing and amount of capital expenditures, credit facility availability and limitations on distributions existing thereunder, and other factors beyond the Company’s control. Further, the ability of the Company to pay dividends will be subject to applicable laws, including satisfaction of solvency tests under the Business Corporations Act (Alberta), and satisfaction of certain applicable contractual restrictions contained in the agreements governing the Company’s outstanding indebtedness. Further, the actual amount, the declaration date, the record date and the payment date of any dividend are subject to the discretion of the InPlay Board of Directors. There can be no assurance that InPlay will pay dividends in the future.

The forward-looking information and statements included herein are not guarantees of future performance and should not be unduly relied upon. Such information and statements, including the assumptions made in respect thereof, involve known and unknown risks, uncertainties and other factors that may cause actual results or events to defer materially from those anticipated in such forward-looking information or statements including, without limitation: changes in industry regulations and legislation (including, but not limited to, tax laws, royalties, and environmental regulations); the risk that the Pembina Cardium asset acquisition may not be completed on the anticipated terms or timing; risks related to an international trade war, including the risk that the U.S. government imposes additional tariffs on Canadian goods, including crude oil and natural gas, and that such tariffs (and/or the Canadian government’s response to such tariffs) adversely affect the demand and/or market price for InPlay’s products and/or otherwise adversely affects InPlay, or lead to the termination of InPlay’s financing arrangements for the Pembina Cardium asset acquisition, including specifically that the imposition of tariffs or similar measures in excess of 10% would be an adverse tariff event for the purposes of InPlay’s new credit facilities to be entered into in connection with the transaction and that the lenders thereunder may choose not to fund the transaction; the continuing impact of the Russia/Ukraine conflict and war in the Middle East; potential changes to U.S. economic, regulatory and/or trade policies as a result of a change in government; inflation and the risk of a global recession; changes in our planned 2025 capital program; changes in our approach to shareholder returns; changes in commodity prices and other assumptions outlined herein; the risk that dividend payments may be reduced, suspended or cancelled; the potential for variation in the quality of the reservoirs in which InPlay operates; changes in the demand for or supply of InPlay’s products; unanticipated operating results or production declines; changes in tax or environmental laws, royalty rates or other regulatory matters; changes in development plans or strategies of InPlay or by third party operators of InPlay’s properties; changes in InPlay’s credit structure, increased debt levels or debt service requirements; inaccurate estimation of InPlay’s light crude oil and natural gas reserve and resource volumes; limited, unfavorable or a lack of access to capital markets; increased costs; a lack of adequate insurance coverage; the impact of competitors; and certain other risks detailed from time-to-time in InPlay’s continuous disclosure documents filed on SEDAR+ including InPlay’s Annual Information Form dated March 27, 2024 and the annual management’s discussion & analysis for the year ended December 31, 2024.

This document contains future-oriented financial information and financial outlook information (collectively, “FOFI”) about InPlay’s financial and leverage targets and objectives, potential dividends, and beliefs underlying our Board approved 2025 capital budget and associated guidance, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. The actual results of operations of InPlay and the resulting financial results will likely vary from the amounts set forth in this document and such variation may be material. InPlay and its management believe that the FOFI has been prepared on a reasonable basis, reflecting management’s reasonable estimates and judgments. However, because this information is subjective and subject to numerous risks, it should not be relied on as necessarily indicative of future results. Except as required by applicable securities laws, InPlay undertakes no obligation to update such FOFI. FOFI contained in this document was made as of the date of this document and was provided for the purpose of providing further information about InPlay’s anticipated future business operations and strategy. Readers are cautioned that the FOFI contained in this document should not be used for purposes other than for which it is disclosed herein.

The forward-looking information and statements contained in this document speak only as of the date hereof and InPlay does not assume any obligation to publicly update or revise any of the included forward-looking statements or information, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws.

Risk Factors to FLI

Risk factors that could materially impact successful execution and actual results of the Company’s 2025 capital program and associated guidance and estimates include:

risks related to an international trade war, including the risk that the U.S. government imposes additional tariffs on Canadian goods, including crude oil and natural gas, and that such tariffs (and/or the Canadian government’s response to such tariffs) adversely affect the demand and/or market price for the Company’s products and/or otherwise adversely affects the Company;
volatility of petroleum and natural gas prices and inherent difficulty in the accuracy of predictions related thereto;
the extent of any unfavourable impacts of wildfires in the province of Alberta.
changes in Federal and Provincial regulations;
the Company’s ability to secure financing for the Board approved 2025 capital program and longer-term capital plans sourced from AFF, bank or other debt instruments, asset sales, equity issuance, infrastructure financing or some combination thereof; and
those additional risk factors set forth in the Company’s MD&A and most recent Annual Information Form filed on SEDAR+.

SOURCE InPlay Oil Corp.

For further information please contact: Doug Bartole, President and Chief Executive Officer, InPlay Oil Corp., Telephone: (587) 955-0632; Kevin Leonard, Vice President, Business Development, InPlay Oil Corp., Telephone: (587) 893-6804

Release – ISG to Announce First-Quarter Financial Results

Posted on April 7, 2025April 7, 2025 by aweinsoff@channelchek.com

Research News and Market Data on III

4/7/2025

STAMFORD, Conn.–(BUSINESS WIRE)– Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, said today it will release its first-quarter financial results on Thursday, May 8, 2025, at approximately 4:15 p.m., U.S. Eastern Time.

The firm will host a conference call with investors and industry analysts at 9 a.m., U.S. Eastern Time, the following day, Friday, May 9. Dial-in details are as follows:

The dial-in number for U.S. participants is+1 (800) 715-9871.
International participants should call+1 (646) 307-1963.
The security code to access the call is9414856.

Participants are requested to dial in at least five minutes before the scheduled start time.

A recording of the conference call will be accessible on ISG’s investor relations page for approximately four weeks following the call.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.

Release – V2X to Showcase Readiness Innovations at 2025 Sea-Air-Space Exposition

Posted on April 7, 2025April 7, 2025 by aweinsoff@channelchek.com

Research News and Market Data on VVX

April 07, 2025

Download(opens in new window)

RESTON, Va., April 7, 2025 /PRNewswire/ — V2X (NYSE: VVX) will highlight its latest readiness innovations at the 2025 Sea-Air-Space Exposition, hosted by the Navy League of the United States, from April 7–9 at the Prince George’s Exhibit Hall. Attendees can visit V2X at Booth 200 to explore solutions designed to enhance the operational effectiveness of the U.S. Navy, U.S. Marine Corps, and other defense customers. Throughout the event, V2X will feature a range of solutions that advance readiness and meet the evolving demands of modern missions, including:

Weapon System Integration

V2X develops, integrates, and sustains mission-critical weapon system capabilities to enhance combat readiness across airborne platforms. V2X delivers secure, platform-agnostic Weapon System Integration (WSI) solutions, ensuring warfighters can rapidly adapt to emerging threats.

Enables enhanced weapons carriage and deployment across fourth- and fifth-generation aircraft.
Supports real-time sense, control, and engagement for greater operational effectiveness.

Enhanced Situational Awareness for Air-to-Ground Operations

V2X will also highlight its advanced communications and situational awareness solutions that enable seamless, multi-domain integration on the battlefield.

The Gateway Mission Router (GMR) provides secure, real-time connectivity across airborne and ground platforms, delivering a Common Operating Picture for enhanced warfighter situational awareness.
GMR integrates with existing platform communications, optimizing data flow while maintaining a low size, weight, power, and cost (SWaP-C) footprint.
New capabilities include Wireless Intercom and Maintenance Data Offload, reinforcing V2X’s support for the DoD’s Combined Joint All-Domain Command and Control initiative.

Full-Spectrum Aviation Readiness

With decades of performance, V2X delivers full-spectrum aviation readiness that keeps more than 1,600 aircraft mission-ready—earning top performance scores across the defense aviation industry. By leveraging advanced technologies and data analytics, V2X provides real-time visibility into flight operations, maintenance, readiness, and supply chains. Our vertically integrated capabilities—ranging from organic engineering and rapid prototyping to four FAA-certified Part 145 repair stations—support critical maintenance, upgrades, and modifications that drive industry-leading aircraft availability rates. V2X’s long-standing support of the Navy’s T-45 and C-12 programs underscores its track record of exceeding expectations and delivering measurable readiness gains.

Visit Booth 200 to meet V2X leaders and explore how the company is advancing aviation readiness and reinforcing its commitment to the Navy, Marine Corps, and mission success across the force.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Marketing and Communications
Angelica.Deoudes@goV2X.com
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-to-showcase-readiness-innovations-at-2025-sea-air-space-exposition-302421316.html

SOURCE V2X, Inc.